A research publication from the journal “Cancer Letters” has studied the use of a new drug, IP1867B, in cancer treatment. The study has found that it may increase the efficacy of cancer therapies. Also, IP1867B may restore sensitivity to a few cancer treatments.
IP1867B is effective in reducing the growth of glioblastoma tumors
Cancer is an abnormal growth of cells, that can also spread to other parts of the body. Many factors can limit the success rate of cancer therapies. These factors include too many side effects of treatment and failure to enter the blood-brain barrier.
The ability of the tumors to hide and resist treatment may also limit the efficacy. IP1867B is reformulated liquid aspirin. That is a mixture of triacetin, saccharin, and aspirin. And the study has shown that it helps to avoid these factors.
The research team has found that IP1867B has led to a decrease in the size of adult high-grade glioma brain tumors. And it has also reduced the GIT problems faced while taking aspirin tablets.
IP1867B may be efficient against glioblastoma (GBM). GBM is one of the most destructive forms of brain cancers in humans and kills thousands of patients per year.
Producing a fully new drug is costly and requires many years. By making efforts to test new formulation methods, scientists can get a step closer to cancer treatment.
Analyzing the drugs that will safely and positively combine with IP1867B can further increase the efficacy of cancer therapies. It may also reduce the need for continuous use. Still, there is a need to do more work before using IP1867B in future treatments of cancer.
IB1867B can lower the activity of EGFR and IGF-1 Pathway and reverse the acquired resistance
The research team has carried out many tests in mice in the labs. They have used adult cancer cells with brain tumors and tested various drugs. In these tests, the team has also included the three key components of the drug IP1867B.
The results of the tests have shown that IP1867B was more effective than some chemotherapeutics (currently used) and any other combination of components. The study has found that all three elements of IP1867B allowed for use in the clinics, can kill tumor cells.
Also, they have no negative effect on normal cells of the brain. The research team has further noticed that IP1867B lowers the activity of Epithelial Growth Factor Receptor (EGFR). And it can also block the IGF-1 pathway, decreasing the tumor’s ability to develop resistance against these EGFR inhibitors.
The tumors that may create resistance using the IGF-1 pathway may pose a problem for cancer treatments. While IP1867B can affect multiple targets and reverse this resistance. A brain tumor is a complex form of cancer. And the work on combining various drugs is important for making advancements in the fight against this tumor.
Using the existing and already approved (for humans use) drugs in new ways to treat brain tumors, can give more hope for the future. In short, using IP1867B increases the efficacy of cancer therapies.
This drug can not only shrink the size of tumors but can also uncover them. Exposing the tumors may permit other therapies to attack them. Turning cold tumors hot, reducing side effects, reversing the resistance of tumors, and increasing the efficacy of other therapies makes IP1867B a fruitful step in the cancer treatment.